Volume 183, Issue 3 pp. 129-133
Research

Pethidine in emergency departments: promoting evidence-based prescribing

Karen I Kaye BPharm, DHP

Karen I Kaye BPharm, DHP

Executive Officer

NSW Therapeutic Advisory Group Inc, Sydney, NSW.

Search for more papers by this author
Susan A Welch BPharm

Susan A Welch BPharm

Project Officer; and Senior and Emergency Pharmacist, St Vincent's Hospital, Sydney

NSW Therapeutic Advisory Group Inc, Sydney, NSW.

Search for more papers by this author
Sharon R Davis BPharm, DipNut

Sharon R Davis BPharm, DipNut

Research and Liaison Officer

NSW Therapeutic Advisory Group Inc, Sydney, NSW.

Search for more papers by this author
Linda V Graudins BPharm, DHP, FSHPA

Linda V Graudins BPharm, DHP, FSHPA

Senior Pharmacist; and Honorary Lecturer, University of Sydney; and Chair, NSW TAG Drug Usage Evaluation Support Group

NSW Therapeutic Advisory Group Inc, Sydney, NSW.

Search for more papers by this author
Andis Graudins FACEM, PhD

Andis Graudins FACEM, PhD

Emergency Physician and Director, Clinical and Experimental Toxicology Unit, Department of Emergency Medicine; and Senior Lecturer (Conjoint), University of New South Wales

Prince of Wales Hospital.

Search for more papers by this author
Tai Rotem BSOCSCI

Tai Rotem BSOCSCI

Statistician

School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW.

Search for more papers by this author
Richard O Day MD, FRACP

Richard O Day MD, FRACP

Clinical Pharmacologist and Head; and Professor, University of New South Wales

Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, NSW.

Search for more papers by this author
First published: 01 August 2005
Citations: 16

Abstract

Objective: To reduce pethidine prescribing in hospital emergency departments (EDs).

Design: Multi-centre drug use evaluation (DUE) process.

Setting and participants: Emergency departments in 23 public hospitals (22 in New South Wales, 1 in Victoria) from 1 September 2002 to 31 August 2003. Participating hospitals included seven principal referral hospitals, six major non-teaching hospitals and 10 district or community hospitals. Data for comparison were collected from 12 non-participating hospitals.

Interventions: Hospital coordinators at each participating hospital were provided with support to implement a range of prescribing interventions in their ED in each of three DUE cycles. Interventions included educational materials (guidelines, posters, prescribing reminders), audit and feedback, and small-group discussions. Three audits of pethidine prescribing were undertaken. Prescribing was compared with evidence-based guidelines and non-concordance identified.

Main outcome measures: Number of dosage units of parenteral analgesics issued to the ED from each hospital's pharmacy department was recorded monthly and aggregated in 3-month periods.

Results: In the 12 months between the preintervention period and the equivalent post-intervention period, pethidine use decreased by 62% in project hospitals (4669 to 1793 units) and 56% in control hospitals (1476 to 648 units). Six months after project completion there was a significantly greater reduction from baseline in participating hospitals (71%; 4669 to 1348 units) compared with non-participating hospitals (64%; 1476 to 532 units; P < 0.001). There was a concurrent increase in use of both morphine and tramadol.

Conclusion: There was a sustained reduction in pethidine use during the study period, which may indicate successful promotion of safer analgesic prescribing. It is not clear whether changes were a result of collaborative DUE methods or other factors.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.